Search
Search Results
##search.searchResults.foundPlural##
-
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2262PDF: 1815HTML: 831 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
3234PDF: 961HTML: 2710 -
ASSOCIATION OF BASELINE PLATELET COUNT WITH COMPLETE REMISSION, SEVERE BLEEDING, AND 24-MONTH OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A SINGLE-CENTER RETROSPECTIVE COHORT STUDY
0PDF: 0Suppl. Files: 0Html: 0Html Suppl. Files: 0 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
2980PDF: 1405HTML: 3722Untitled: 212Untitled: 226Untitled: 197 -
CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL
4523PDF: 3710HTML: 368 -
PERSISTENT COLONIC SCHISTOSOMIASIS AMONG SYMPTOMATIC RURAL INHABITANTS IN THE EGYPTIAN NILE DELTA Colonic schistosomiasis among rurals of the Egyptian Nile delta
1648PDF: 526MP4: 442Html: 295 -
CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA CAR T Cells and Myeloma Treatment
1813PDF: 891HTML: 1217 -
BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL
1714PDF: 1131HTML: 166 -
The MINI-POLATUZUMAB VEDOTINE PLUS CHP (POLA-R-CHP) VS. MINI-R-CHOP IN PATIENTS OVER 80 YEARS OF AGE WITH DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE, PROPENSITY SCORE-MATCHED ANALYSIS STRATIFIED BY SIMPLIFIED FRAILTY SCORE PolaRCHP vs. RCHOP for older patients
1425PDF: 474HTML: 124 -
-
PREVALENCE OF SICKLE CELL TRAIT IN THE SOUTHERN SUBURBS OF BEIRUT, LEBANON
4200PDF: 1031HTML: 19210 -
Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA
1757PDF: 1306HTML: 577 -
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
4233Suppl. Files: 1200PDF: 1119Html: 252 -
CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA CAR-T; Large B Cell Lymphoma; Salvage Therapy,
3825PDF: 1521HTML: 330 -
IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy
1798PDF: 830HTML: 226 -
ENDOTHELIAL BIOMARKERS IN PATIENTS RECOVERED FROM COVID-19 ONE YEAR AFTER HOSPITAL DISCHARGE: A CROSS-SECTIONAL STUDY Endothelial biomarkers in COVID-19 recoverers one year after hospital discharge.
1360PDF: 774HTML: 408 -
HEPARIN-BINDING PROTEIN AS A DIAGNOSTIC AND PROGNOSTIC MARKER OF INFECTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS Heparin-binding protein in adult patients
3008PDF: 1064HTML: 266Suppl. Files: 528 -
COMPARATIVE ANALYSIS OF CLINICAL AND LABORATORY DATA IN CHILDREN WITH MULTISYSTEM INFLAMMATORY SYNDROME ASSOCIATED WITH SARS-COV-2 IN THE REPUBLIC OF KAZAKHSTAN MULTISYSTEM INFLAMMATORY SYNDROME ASSOCIATED WITH SARS-COV-2
1127PDF: 602HTML: 380 -
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
4933PDF: 2913HTML: 2337 -
PREVALENCE OF HEPATITIS B, HEPATITIS C AND HIV IN MULTIPLY TRANSFUSED SICKLE CELL DISEASE PATIENTS FROM OMAN HBV,HCV and HIV and Sickle Cell Disease.
1702PDF: 1037HTML: 550 -
LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM? Letermovir and Cytomegalovirus Prophylaxis in HSCT
1539PDF: 1054HTML: 134 -
CYTOMEGALOVIRUS REACTIVATION IN ADULT RECIPIENTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
1587PDF: 918HTML: 1016figures: 206table 1: 205table2: 200table3: 205 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
2045PDF: 1399HTML: 799 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1488PDF: 1363HTML: 111 -
GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload
4020PDF: 1161HTML: 466







